Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AET BioTech, BioXpress partner on biosimilar
December 2012
SHARING OPTIONS:

GENEVAŚAET BioTech, the biosimilars business within AET Group, and BioXpress Therapeutics SA have announced an agreement to co-develop a biosimilar version, based on BioXpress technology, of the TNF inhibitor MAb Adalimumab. The partners will be jointly responsible for development, registration and manufacture of the biosimilar. AET BioTech will be responsible for providing further investment in the biosimilar based on committed long-term financing, as well as any future commercialization. No financial details were disclosed.  
 
"The BioXpress team has an impressive track record in the development of the initial originator MAbs, and access to state-of-the-art MAb know-how and technology, and the partnership will unite our technical and commercial strengths behind the Adalimumab biosimilar," Dr. Harm Peters, managing director of AET BioTech, said in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.